Език: EN EN
← Назад към резултатите
Одобрено за пазара NCT00094029

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Заболявания: Gastrointestinal Neoplasm

Спонсор: Pfizer

Налично на: БГ
Обобщение
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.
Описание
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181036 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
Кой може да участва
Inclusion Criteria: * Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy * Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies * Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician * Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment * Male or Female, 18 years or older * Resolution of all acute toxicities of prior therapies * Adequate organ function Exclusion Criteria: * Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the last 6 months, or ongoing severe or unstable angina or any unstable arrhythmia requiring medication * Symptomatic central nervous system metastases * Serious acute or chronic illness * Current treatment on another clinical trial * Pregnant or breastfeeding.
Места на провеждане 31
Argentina (1)
Pfizer Investigational Site
Burnos Aires
Австралия (1)
Pfizer Investigational Site
Camperdown , New South Wales
Белгия (1)
Pfizer Investigational Site
Brussels
Канада (1)
Pfizer Investigational Site
Calgary , Alberta
Chile (1)
Pfizer Investigational Site
Santiago , RM
Colombia (1)
Pfizer Investigational Site
Bogota , Cundinamarca
Чехия (1)
Pfizer Investigational Site
Brno
Дания (1)
Pfizer Investigational Site
Aarhus C
Финландия (1)
Pfizer Investigational Site
Helsinki
Франция (1)
Pfizer Investigational Site
Bordeaux
Гърция (1)
Pfizer Investigational Site
Thessaloniki
Hong Kong (1)
Pfizer Investigational Site
Happy Valley , Hong Kong
Унгария (1)
Pfizer Investigational Site
Budapest
Индия (1)
Pfizer Investigational Site
Mumbai , Maharashtra
Израел (1)
Pfizer Investigational Site
Tel Aviv
Италия (1)
Pfizer Investigational Site
Candiolo (TO) , Italy
Mexico (1)
Pfizer Investigational Site
Guadalajara , Jalisco
Нидерландия (1)
Pfizer Investigational Site
Groningen , Provincie Groningen
Норвегия (1)
Pfizer Investigational Site
Oslo
Полша (1)
Pfizer Investigational Site
Warsaw
Сингапур (1)
Pfizer Investigational Site
Singapore
Словакия (1)
Pfizer Investigational Site
Bratislava , Bratislava Region
Южна Корея (1)
Pfizer Investigational Site
Seoul
Испания (1)
Pfizer Investigational Site
Barcelona , Barcelona
Швеция (1)
Pfizer Investigational Site
Gothenburg
Taiwan (1)
Pfizer Investigational Site
Kaohsiung Hsien
Тайланд (1)
Pfizer Investigational Site
Ratchatawi , Bangkok
Турция (1)
Pfizer Investigational Site
Ankara
Великобритания (1)
Pfizer Investigational Site
Leeds , England
САЩ (1)
Pfizer Investigational Site
Duarte , California
Venezuela (1)
Pfizer Investigational Site
Caracas , Distrito Federal
Технически детайли
Статус
Одобрено за пазара
Вид изследване
EXPANDED_ACCESS
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
01.09.2004
Крайна дата
01.10.2011
Регистрационен номер
NCT00094029
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.